Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
OpenAI Rejects Apple Trade Secret Theft Claims 
Add as a preferred source on Google
WESTLAKE VILLAGE, Calif., March 06, 2018 -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the Cowen and Company 38th Annual Health Care Conference, Monday, Mar. 12, 2018, 11:20 a.m. EDT, in Boston.
The presentation will be webcast live and can be accessed through the Investor Relations section of the Company’s website at Investors.SiennaBio.com. An archived version of the webcast will be available approximately two hours following the live presentation for 90 days.
About Sienna Biopharmaceuticals
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The Company’s objective is to develop an innovative, diversified, multi-asset pipeline of topical therapies that enhance the health, appearance and quality of life of dermatology and aesthetics patients. Sienna is led by a management team with extensive experience in product development and commercialization at several leading dermatology, aesthetics and biotechnology companies.
For more information, visit the Company’s website at www.SiennaBio.com.
Contact (Investors and Media):
Ric Peterson
Chief Financial Officer
[email protected]
818-629-2232
Sean Andrews
Senior Director, Investor Relations
[email protected]
818-629-2244
